Solesence, Inc. Common Stock

Day range

$0.80 – $0.83

Open

$0.80

Prev close

$0.80

Volume

8.64K

Market cap

$56.52M

Shares out

70.65M

P/E

—

P/S

1.02

P/B

4.30

P/FCF

—

ROE

-14.3%

ROA

-4.0%

Debt/Equity

0.36

Div yield

0.00%

As of Oct 23, 2026

• Credit facilityOct 5, 2026

  On September 30, 2026, Solésence, Inc. entered into a “Fourth Amendment to Business Loan Agreement” with Strandler, LLC, a “Fourth Amendment to Amended and Restated Business Loan Agreement” with Beachcorp, LLC, and a “Fourth Amendment to Business Loan Agreement” with Beachcorp. The Loan Agreement Amendments extended the maturity date under each respective loan agreement from April 30, 2027 to May 31, 2028.

• Listing deficiency noticeOct 2, 2026

  On September 29, 2026, Solésence, Inc. received a written notice from Nasdaq indicating that, because the closing bid price for the Company's common stock has fallen below $1.00 per share for 30 consecutive trading days, the Company was no longer in compliance with the $1.00 Minimum Bid Price requirement set forth in Nasdaq Listing Rule 5550(a)(2).

• Financial restatementAug 21, 2026

  the Company's previously issued consolidated financial statements as of and for December 31, 2023, March 31, 2024, June 30, 2024, September 30, 2024, December 31, 2024, March 31, 2025, June 30, 2025, September 30, 2025, December 31, 2025 and March 31, 2026 should no longer be relied upon and should be restated.

• Settlement agreementJul 10, 2026

  On July 6, 2026, Solésence, LLC entered into a Settlement Agreement and Release with Refy Beauty Ltd to settle and compromise disputes relating to certain consumer care products previously sold by Solésence to Refy. Solésence agreed to pay Refy the British Pound Sterling equivalent of $938,000 in twelve equal installments of $78,166.66 with the first installment due on August 5, 2026.

• Director appointmentApr 29, 2026

  Effective April 24, 2026, the Board of Directors of the Company (the "Board") appointed Marc James to serve as a Class II Director of the Board for the remainder of the term of Class II Directors of the Board, expiring at the 2026 Annual Meeting of Shareholders of the Company. Mr. James has been appointed to the following committees of the Board: Audit and Finance Committee, Compensation Committee, and Nominating and Corporate Governance Committee.

Days to cover

25.1

Short interest

381.66K

Avg volume

15.23K

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Solésence Named Contract Manufacturing Partner of the Year in the 2026 Cosmetics Business Innovation Awards
  positiveGlobeNewswire Inc.· Jun 18, 2026
• Solésence Supports Landmark Report on UV Safety in the United Kingdom as Member of UV Safety Coalition
  positiveGlobeNewswire Inc.· May 14, 2026
• Solésence Reports Third Quarter 2025 Financial Results
  negativeGlobeNewswire Inc.· Nov 11, 2025
• Solésence, Inc. Appoints Yoana Dvorzsak as Vice President of Innovation and Product Integrity
  positiveGlobeNewswire Inc.· Nov 10, 2025